A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan

Trial Profile

A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Dec 2017 Primary endpoint (Objective Response Rate (ORR) has been met, according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results (n=82) assessing efficacy of Lenalidomide, Dexamethasone and Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Nov 2017 According to a Bristol-Myers Squibb media release, data of the trial will be present at the 59th Annual Meeting & Exposition of the American Society of Hematology 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top